DraflazineAlternative Names: R 70380
Latest Information Update: 11 Jun 2000
Price : $50 *
At a glance
- Originator Janssen L.P.
- Developer Janssen L.P.; Nonindustrial source
- Class Antiplatelets; Piperazines
- Mechanism of Action Purinergic P1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis
Most Recent Events
- 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Belgium (Unknown route)
- 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Netherlands (Unknown route)
- 11 Jun 2000 Discontinued-Preclinical for Ischaemic heart disorders in Norway (Unknown route)